Winona BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Winona a Legitimate Company?

Winona operates as a licensed telehealth platform that connects patients with physicians who prescribe hormone therapy for menopause. The company is registered in the United States, uses licensed prescribers, and routes prescriptions through state-licensed compounding pharmacies. That structure is legal under current federal and state law.

Legitimacy, though, is not a binary label. A company can be legally operating while still generating consumer complaints about billing practices or product delays. The sections below examine each dimension separately.

Physician Licensure and Prescribing Model

Winona uses an asynchronous or synchronous telehealth intake model. Prescribers must hold active state medical licenses in the states where they treat patients. The Federation of State Medical Boards maintains a public physician data center where patients can verify any prescriber's license status at https://www.fsmb.org/physician-data-center/. Patients should run that check before their first prescription is filled.

Compounding Pharmacy Oversight

Winona dispenses compounded hormones through 503A compounding pharmacies. Under 21 U.S.C. § 503A, these pharmacies must receive valid patient-specific prescriptions, use approved bulk drug substances, and comply with USP quality standards [1]. The FDA's current guidance on compounding under Section 503A is publicly available and details which bulk substances are permissible [2]. Violations can result in warning letters, import alerts, or pharmacy closure, consequences that would directly interrupt a patient's prescription access.

BBB Profile and Complaint Patterns

The Better Business Bureau is not a government regulator. Its ratings reflect how a company responds to complaints, not whether its products are safe or clinically appropriate. Winona does not hold BBB accreditation as of January 2025.

Volume and Category of Complaints

Winona's BBB file contains a modest number of consumer complaints relative to its reported subscriber base. The publicly visible complaints cluster around three categories:

• Billing and subscription: Charges continuing after cancellation requests, difficulty reaching customer service to stop recurring payments.
• Shipping delays: Compounded prescriptions arriving later than promised, with patients missing doses.
• Refund disputes: Disagreements over whether consultations or products are refundable after delivery.

These categories are not unique to Winona. A 2022 analysis published in the Journal of the American Medical Association examined direct-to-consumer telehealth platforms broadly and found that billing transparency and care continuity were the most common complaint domains across the sector [3].

BBB Response Rate

The BBB grades partly on whether a business responds to complaints. Winona's response rate on file suggests the company does engage with BBB dispute processes, which is relevant context when comparing it to platforms that ignore complaints entirely. A response, however, does not mean the underlying issue was resolved to the patient's satisfaction.

Consumer Complaint Triage Framework for Telehealth HRT Platforms

When evaluating any telehealth complaint file, use this four-factor filter before drawing conclusions:

1. Complaint volume normalized to patient volume. Ten complaints from 500 patients is different from ten complaints from 50,000 patients. BBB files rarely disclose subscriber counts, so treat raw numbers cautiously.
2. Complaint category. Billing complaints suggest operational problems. Clinical-harm complaints suggest patient-safety problems. The two carry different risk weights.
3. Resolution rate. Were complaints closed with resolution or closed without resolution? The BBB distinguishes these.
4. Recency trend. A spike in complaints after a platform change (new pharmacy, new billing system) may be transient rather than structural.

FDA Regulatory Framework for Compounded Hormones

The FDA does not approve compounded hormone preparations for safety or efficacy the way it approves commercial drugs. That regulatory gap is the single most important clinical fact for any patient considering a compounding-based HRT service.

What 503A Means in Practice

A 503A pharmacy can legally compound estradiol, progesterone, or testosterone for individual patients when a licensed prescriber writes a patient-specific prescription. The pharmacy must use bulk substances from FDA-registered manufacturers and follow USP Chapter 795 standards for non-sterile preparations and USP Chapter 797 for sterile preparations [4]. The FDA published revised USP 795 and 797 guidance in 2023, tightening stability-testing and beyond-use dating requirements that directly affect compounded hormone products [5].

FDA Warning Letters Relevant to Compounded HRT

The FDA has issued warning letters to multiple compounding pharmacies over the past decade for cGMP violations, adulteration, and mislabeling of hormone products. A searchable database of FDA warning letters is available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters [6]. Patients can search for any pharmacy by name to see whether it has received enforcement action. This step takes under two minutes and is the most direct regulatory check available before filling a prescription.

Bioidentical Hormone Claims and FDA Position

Winona, like most compounded HRT platforms, markets "bioidentical" hormones. The FDA has stated explicitly that the term "bioidentical" is not a regulatory category and that bioidentical compounded hormones have not been proven safer or more effective than FDA-approved hormone products [7]. The North American Menopause Society (NAMS) echoes this: its 2022 Position Statement states, "Bioidentical compounded hormone therapy is not recommended as a first-line therapy due to concerns about efficacy, safety, and quality" [8].

State Pharmacy Board Oversight

Each state pharmacy board independently licenses and inspects pharmacies operating within its borders. A telehealth platform can route prescriptions to pharmacies in states with stronger or weaker inspection programs. That variation in oversight is a real source of quality risk.

How to Verify a Compounding Pharmacy's License

Every licensed pharmacy in the United States holds a National Provider Identifier (NPI). Patients can verify NPI records through the CMS National Plan and Provider Enumeration System at https://npiregistry.cms.hhs.gov/ [9]. After confirming the NPI, they should cross-check with the relevant state pharmacy board to confirm the license is active and free of disciplinary actions. Most state boards list disciplinary actions publicly; links to all 50 state boards are maintained by the National Association of Boards of Pharmacy (NABP) at https://nabp.pharmacy/boards-of-pharmacy/ [10].

NABP Not-Recommended List

The NABP maintains a "Not Recommended" list of online pharmacies that fail its safety criteria. This list covers both traditional online pharmacies and some compounding operations. Checking whether Winona's dispensing pharmacy appears on this list is a straightforward safety step [10].

Clinical Appropriateness: What the Guidelines Say

Consumer complaints about billing are separate from whether the underlying treatment is appropriate. Menopausal hormone therapy has a strong evidence base when prescribed to the right patient.

NAMS 2022 Position Statement

The NAMS 2022 Position Statement on hormone therapy is the most widely cited guideline in North American menopause care. It concludes that for women under 60 or within 10 years of menopause onset, the benefits of HRT outweigh the risks for treatment of vasomotor symptoms [8]. The statement specifically addresses cardiovascular and breast-cancer risk stratification, which prescribers at any telehealth platform should assess before initiating therapy.

WHI Data in Context

The Women's Health Initiative (WHI) trials, published in JAMA in 2002 and 2004, generated lasting concern about HRT safety [11]. The combined estrogen-plus-progestin arm (N=16,608) showed a hazard ratio of 1.26 for invasive breast cancer over 5.6 years of follow-up [11]. Subsequent reanalysis, including the 2017 JAMA paper by Manson et al. (N=27,347 cumulative), showed that timing of initiation relative to menopause onset significantly modifies cardiovascular risk [12]. A telehealth prescriber who does not conduct a thorough intake review cannot responsibly apply this nuance.

Testosterone in Women

Winona also offers testosterone for women, typically for low libido. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (N=8,480 across 46 randomized trials) found that testosterone improved sexual function scores significantly compared to placebo, but noted that long-term safety data beyond 24 months remain limited [13]. Patients prescribed testosterone through any telehealth platform should ask their provider about monitoring free testosterone levels and hematocrit at baseline and at 3 months.

Pricing, Subscription Model, and Billing Transparency

Winona operates on a subscription or membership model. Patients pay a recurring fee that covers the consultation and, in some tiers, the medication cost. This bundled structure is common in cash-pay telehealth but creates a specific complaint risk: patients who want to cancel can face friction if the cancellation process is unclear or if billing cycles do not align with their expectations.

Key Questions to Ask Before Subscribing

• What is the cancellation policy, and is it available in writing before payment?
• Does the subscription auto-renew, and what notice period triggers the next billing cycle?
• Are consultations refundable if no prescription is issued?
• Is the dispensing pharmacy disclosed by name before the first prescription is sent?

The Federal Trade Commission's "Negative Option Rule," finalized in 2024, requires subscription services to make cancellation as easy as enrollment [14]. Patients who believe a telehealth subscription violated these requirements can file a complaint directly with the FTC at https://reportfraud.ftc.gov/.

How Winona Compares to Other Telehealth Menopause Platforms

Winona competes with platforms including Midi Health, Evernow, Alloy, and Gennev. Each uses a variation of the asynchronous telehealth model and each routes compounded or FDA-approved hormones to patients. The complaint categories visible across these platforms in public BBB and Trustpilot files are nearly identical: billing, shipping, and cancellation.

What Differentiates Platforms Operationally

The meaningful clinical differentiators are:

• Whether the platform uses synchronous (live video) or asynchronous (questionnaire-only) prescribing. Asynchronous models may miss clinical nuance.
• Whether lab work is required before prescribing hormones. Prescribing estradiol without baseline FSH, estradiol, or thyroid function testing is a gap some platforms tolerate.
• Whether a follow-up visit is included at 3 months to assess response and adjust dose.

The Endocrine Society's 2015 clinical practice guideline on menopause management recommends individualized assessment including symptom severity, cardiovascular risk factors, and prior breast cancer history before initiating systemic HRT [15]. A platform that skips this step raises a clinical quality concern independent of its BBB profile.

Red Flags and Green Flags When Evaluating Any HRT Telehealth Service

Red Flags

• No disclosure of the dispensing pharmacy's name and state license number
• No requirement for any lab work before or after starting hormones
• Cancellation process requires phone call only, with no written confirmation
• Marketing that claims compounded hormones are "safer" than FDA-approved products, which contradicts FDA guidance [7]
• Prescriber is not licensed in the patient's state

Green Flags

• Dispensing pharmacy is PCAB-accredited (Pharmacy Compounding Accreditation Board)
• Follow-up visit is scheduled within 90 days of initiation
• Prescriber reviews personal and family history of breast cancer, cardiovascular disease, and thromboembolic events
• Platform provides written informed consent about the difference between compounded and FDA-approved hormone products
• Cancellation is available online without a required phone call

What Patients Should Do Before Starting Winona or Any Comparable Service

1. Verify the prescribing physician's license using the FSMB Physician Data Center.
2. Ask Winona (or any platform) for the name and NPI of the dispensing pharmacy before the first prescription is filled.
3. Cross-check that pharmacy against the NABP Not-Recommended list and state board disciplinary records.
4. Search the FDA warning letter database for the pharmacy's name.
5. Review the NAMS 2022 Position Statement summary at https://www.menopause.org/ [8] so you can evaluate whether the prescriber's recommendations align with current evidence.
6. Read the subscription agreement, specifically the auto-renewal clause and cancellation terms, before entering payment information.

Patients in states with active telehealth consumer-protection statutes (California, New York, and Texas have enacted relevant provisions) may have additional remedies if a platform engages in deceptive billing. The relevant state attorney general office handles these complaints when FTC jurisdiction is unclear.

A baseline FSH and estradiol level, ordered through any lab, costs roughly $40 to $80 without insurance and gives any prescriber, telehealth or in-person, the data needed to confirm whether hormone therapy is clinically indicated before the first dose is taken.